Among adults who have a high risk of developing type 2 diabetes, those who were given vitamin D supplements for around 3 years did not appear to have significant differences in kidney function compared to those receiving placebo, revealed a secondary analysis of the Vitamin D and Type 2 Diabetes (D2d) study.

At baseline, most of these adults with prediabetes and obesity or overweight had sufficient serum 25-hydroxyvitamin D (25[OH]D) and a low risk for adverse kidney outcomes. Overall, 2166 participants in D2d with complete kidney function data formed a part of this analysis. They had a mean serum 25(OH) level of 28 ng/mL. Overall, 28 patients in the vitamin D group and 30 patients in the placebo group were found to have deterioration of KDIGO risk score. The mean difference in eGFR from baseline was estimated as –1.0 mL/min/1.73m2 in the vitamin D group and –0.1 mL/min/1.73 m2 in the placebo group. The mean difference in UACR was 2.7 mg/g and 2.0 mg/g in the vitamin D and placebo groups, respectively. There appeared to be no significant between-group differences in these outcomes. The findings are published in the Clinical Journal of the American Society of Nephrology… (Medscape)